GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-08-16| M&A

GSK’s Second Billion Dollar Acquisition Outprices their First of 2022

by Max Heirich
Share To

On August 16, GSK announced the completion of its billion dollar acquisition of Affinivax. Announced in May of this year, GSK paid $2.1 billion upfront to gain access to Affinivax’s next-generation vaccine candidate. This marks the largest acquisition of GSK in 2022, followed closely by their $1.9 billion purchase of Sierra Oncology. 

Related Article: Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition

The $2.1 Billion Acquisition of a Phase II Vaccine

Affinivax is a clinical-stage biopharmaceutical company developing vaccines through their Multiple Antigen Presenting System (MAPS). MAPS supports vaccine creation by simplifying design while simultaneously enhancing the efficacy and breadth of protection. 

The flagship vaccine designed with MAPS is AFX3772, a vaccine in Phase II development that protects against 24 diseases caused by pneumococcal bacteria.

Because of this technology and this vaccine candidate, GSK entered into negotiations for the acquisition of Affinivax; together, they announced a definitive agreement on May 31. In exchange for access to their MAPS technology and the AFX3772 vaccine, GSK offered to pay $0.2 billion over their other completed acquisition of 2022.

GSK’s Second and Largest Acquisition in 2022

On July 1, only a day after the announcement of the acquisition of Affinivax, GSK announced the completion of their acquisition of Sierra Oncology. GSK paid an upfront cost of $1.9 billion, priced at $55 per outstanding share of the company. However, no potential development milestones were agreed upon for products in development, unlike the deal with Affinivax.

The upfront payment for Affinivax beat the price paid for Sierra Oncology, totaling $2.1 billion for 100% of outstanding shares. An additional $1.2 billion is on the line related to milestones associated with certain pediatric clinical development milestones.

On the acquisition, Steven Brugger, CEO of Affinivax, said, “We are proud that GSK has recognized our team’s accomplishments and are confident that GSK is an ideal new home for our MAPS platform and the team behind its success.”

GSK’s billion dollar acquisition follow other significant moves made in the industry this year. Companies like Pfizer and Bristol Myers Squibb made similarly priced acquisitions earlier this year for Biohaven Pharmaceuticals and Turning Point Therapeutics, respectively. With many other acquisitions already underway or completed this year, only time will tell if these acquisitions will remain amongst the most expensive for 2022.

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Teladoc Dials Up Virtual Care with $70 Million Acquisition of Catapult
2025-02-06
JPM 2025’s Billion Dollar Deal – GSK Bids Big in GI Cancer
2025-01-15
GSK Secures Approval From Chinese NMPA for Nucala, its Add-On-Therapy to Treat CRSwNP
2025-01-07
LATEST
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top